The Biden Administration’s plan to reclassify cannabis as a Schedule III drug may be losing momentum following new reports suggesting the administrator of the U.S. Drug Enforcement Administration (DEA) failed to sign the rescheduling order.
What Happened: Several reports from last week indicated that the DEA would move to reclassify marijuana as a less dangerous drug. Although the proposal wouldn’t legalize cannabis for recreational use, it acknowledged that cannabis has medical benefits and places it in a category that recognizes it as having less potential for abuse.
The DEA was expected to move forward with its plans this week to remove cannabis as a Schedule 1 drug, where it currently sits alongside heroin and LSD, but new reports suggest the proposal has stalled.
According to an X post on Monday from Newsweek’s Kevin Sabet, DEA Administrator Anne Milgram failed to sign the rescheduling order.
“BIG: I can now say with full confidence that the Administrator of DEA, Anne Milgram, did NOT sign the rescheduling order, breaking with five decades of precedent and established law and regulations,” Sabet said in the post, citing two confidential sources inside the DEA and another outside source with knowledge on the matter.
Don’t Miss: Criminal Defense Lawyers To Biden: Release Pot Prisoners As DEA Moves To Reclassify Cannabis
Cannabis stocks got a lift last week in anticipation of the rescheduling order. The broader cannabis space pulled back Monday afternoon following new rescheduling order developments.
Here’s a look at some of the biggest movers in the cannabis space on Monday, at market close:
- Canopy Growth Corp CGC: Down 5.08%
- Tilray Brands, Inc TLRY: Down 2.38%
- Curaleaf Hldgs Inc CURLF: Down 0.35%
- Trulieve Cannabis Corp TCNNF: Down 8.78%
- Green Thumb Industries Inc GTBIF: Down 5.15%
- AdvisorShares Pure US Cannabis ETF MSOS: Down 2.79%
- AdvisorShares Pure Cannabis ETF YOLO: Down 1.47%
Check This Out: Cannabis Reform Advocate Champions Change, Looks To Expand Prophet Across The Globe
Photo: 7raysmarketing from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.